Hainan Puli Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") received the Shenzhen Stock Exchange's (hereinafter referred to as "SZSE") decision on April 18, 2025, regarding the termination of the listing of the Company's stock and convertible bonds (hereinafter referred to as "convertible bonds") (SZSE Announcement [2025] No. 357). The SZSE decided to terminate the listing of the Company's stock and convertible bonds.
300630SZSE
Announcement on the Company's Application for Review to the Shenzhen Stock Exchange
✨ AI Summary
Hainan Puli Pharmaceutical Co., Ltd. has applied for a review of the Shenzhen Stock Exchange's decision to terminate the listing of its stock and convertible bonds. The review application was submitted on May 12, 2025, following the initial termination notice received on April 18, 2025. The company will continue to disclose information regarding the review process and associated risks to investors.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.